HeartSciences Faces Nasdaq Delisting After Equity Shortfall

summarizeSummary

HeartSciences received a Nasdaq delisting notice after failing the $2.5M equity requirement. The company intends to lean on its pending merger with Fortitude Mining to regain compliance, but failure would likely trigger delisting.

check_boxKey Events · Legal and Risk Events · HSCS

• Nasdaq Delisting Notice Received

  On August 4, 2026, HeartSciences received a Nasdaq deficiency notice for failing to maintain the minimum $2.5 million stockholders' equity requirement, reporting only $226,060 in its latest 10-K.

• Compliance Plan Deadline

  The company has until September 18, 2026, to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 days (until January 31, 2027) to evidence compliance.

• Merger as Compliance Strategy

  HeartSciences intends to use the pending all-stock merger with Fortitude Mining Holdings as the basis for its compliance plan, making the merger critical to maintaining its Nasdaq listing.

• Delisting Risk Amplifies Existing Distress

  The delisting notice compounds existing risks: a going-concern warning, material weaknesses in internal controls, and stockholders' equity of just $0.2 million. Failure to complete the merger or regain compliance could force the stock off Nasdaq.

auto_awesomeAnalysis · HSCS · Crypto Assets

A Nasdaq delisting notice has landed on HeartSciences because its stockholders' equity of $226,060 sits far below the required $2.5 million minimum. The company now has 45 days to submit a compliance plan, which hinges entirely on the pending all-stock merger with Fortitude Mining. Should the plan be rejected or the merger collapse, delisting becomes a near certainty—a severe blow for a firm already wrestling with a going-concern warning and material weaknesses. In effect, the merger has transformed from a strategic pivot into an existential necessity for preserving the Nasdaq listing.